ID

24913

Descripción

Study ID: 100571 (M138) Clinical Study ID: 100571 Study Title: Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00291876 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: Hepatitis A Vaccine, Inactivated Trade Name: Havrix Study Indication: Hepatitis A https://clinicaltrials.gov/ct2/show/NCT00291876

Link

https://clinicaltrials.gov/ct2/show/NCT00291876

Palabras clave

Versiones (2)
  1. 22/8/17 22/8/17 -
  2. 23/8/17 23/8/17 -
Subido en

22 de agosto de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0 Legacy
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

GSK Hepatitis A Vaccine ADDITIONAL VACCINATION MEDICATION NCT00291876

Inglés

GSK Hepatitis A Vaccine ADDITIONAL VACCINATION MEDICATION NCT00291876

1 formularios  
Study administration
Descripción

Study administration

Center
Descripción

Center

Tipo de datos

text

Alias
UMLS CUI [1,1]
C1301943
UMLS CUI [1,2]
C0600091
Date of Visit
Descripción

Date of Visit

Tipo de datos

date

Alias
UMLS CUI [1]
C1320303
Subject Number
Descripción

Subject Identifier

Tipo de datos

integer

Alias
UMLS CUI [1]
C2348585
MEDICATION
Descripción

MEDICATION

Have any of the above mentioned medications/treatments been administered during the period starting 30 days prior to the vaccine dose and ending one month [minimum 30 days] after it?
Descripción

pharmaceutical preparations

Tipo de datos

integer

Alias
UMLS CUI [1]
C0013227
MEDICATION
Descripción

MEDICATION

undefined item
Descripción

undefined item

Tipo de datos

text

Volver a la parte superior de la página

Similar models

GSK Hepatitis A Vaccine ADDITIONAL VACCINATION MEDICATION NCT00291876

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Study administration
Center
Item
Center
text
C1301943 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
Date of Visit
Item
Date of Visit
date
C1320303 (UMLS CUI [1])
Subject Identifier
Item
Subject Number
integer
C2348585 (UMLS CUI [1])
Item Group
MEDICATION
Item
Have any of the above mentioned medications/treatments been administered during the period starting 30 days prior to the vaccine dose and ending one month [minimum 30 days] after it?
integer
C0013227 (UMLS CUI [1])
pharmaceutical preparations
Code List
Have any of the above mentioned medications/treatments been administered during the period starting 30 days prior to the vaccine dose and ending one month [minimum 30 days] after it?
CL Item
No (1)
CL Item
Yes, please complete the following table. (2)
Item Group
MEDICATION
undefined item
Item
text
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial